Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

Effects of Glucagon Like Peptide-1 on No-reflow

NCTNCT02507128 (opens ClinicalTrials.gov in a new tab)Other id301xnk
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
190 participants (estimated)
Sponsor
Chen Wei Ren, MD · Other
Design
Randomized · Double masking
Countries
1 country

China

Start
Jul 2015
Primary completion
Jul 2016 (estimated)
Completion
Jul 2016 (estimated)
First posted
23 Jul 2015 (estimated)
Last update posted
23 Jul 2015 (estimated)
Conditions
Acute ST-segment Elevation Myocardial Infarction

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. N/A

    Effects of Glucagon Like Peptide-1 on No-reflow

    NCT02507128

    Jul 2015 to est. Jul 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).

Interventions

  • liraglutideDrug
  • placeboDrug

Arms2

  • Experimental

    GLP-1 group

    The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).

  • Placebo comparator

    Control group

    the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. a change in the prevalence of no-reflow

    Time frame · immediately after PCI

    Registry description

    The primary efficacy variable was the prevalence of no-reflow assessed immediately post procedure.

Secondary outcomes(3)

  1. a change in troponin T

    Time frame · immediately after PCI, at 1,3,5 days after PCI

    Registry description

    Secondary efficacy variable was troponin T level.

  2. a change in high-sensitivity C-reactive protein (hsCRP)

    Time frame · immediately after PCI, at 1,3,5 days after PCI

    Registry description

    Secondary efficacy variable was high-sensitivity C-reactive protein level.

  3. a change in superoxide dismutase (SOD)

    Time frame · immediately after PCI, at 1,3,5 days after PCI

    Registry description

    Secondary efficacy variable was superoxide dismutase level.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Animal study · 2009

12 results

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

Timmers et al. 2009Journal of the American College of Cardiologycited by 361

PMID 19195607DOI 10.1016/j.jacc.2008.10.033PUB-19195607

Full text at the publisher12 results
Publisher pageSee results (12)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: Patients with ST-segment elevation myocardial infarction were eligible for the study. Exclusion Criteria: Patients were excluded for the following reasons: unconscious at presentation; had cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; had a history of myocardial infarction, stent thrombosis, or renal insufficiency; or had previously undergone coronary artery bypass surgery.

PepBank is a research reference. Talk to a doctor before you use any peptide.